RLAY Relay Therapeutics
- 7.500
- -0.360-4.58%
- 7.500
- 0.0000.00%
Relay Therapeutics News
Relay Therapeutics: A Buy Rating on Robust RLY-2608 Performance and Strategic Trial Design
Relay Therapeutics Price Target Maintained With a $21.00/Share by JMP Securities
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $28
Stifel Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $28
Relay Therapeutics Analyst Ratings
Buy Rating Affirmed for Relay Therapeutics Amid Promising Clinical Outcomes and Strategic Market Positioning
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $17
Barclays Gives a Buy Rating to Relay Therapeutics (RLAY)
Relay Therapeutics' RLY-2608 Shows Superior Efficacy in Breast Cancer Trial, Merits Buy Rating
Relay Upgraded by Jefferies, Downgraded by Oppenheimer
Relay Therapeutics Is Maintained at Overweight by Barclays
Relay Therapeutics Price Target Raised to $17.00/Share From $14.00 by Barclays
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $16 to $24
Jefferies Upgrades Relay Therapeutics to Buy From Hold, Price Target Is $16
Relay Therapeutics Analyst Ratings
Relay Therapeutics' RLY-2608 Shows Promising Efficacy and Safety, Earning a Buy Rating
Buy Rating for Relay Therapeutics Backed by Promising Efficacy and Safety of RLY-2608
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17
BofA Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $20
Analysis
Price Target
No Data
No Data